Revvity, Inc. (RVTY)
- Previous Close
120.23 - Open
120.04 - Bid 119.71 x 1000
- Ask 121.36 x 1000
- Day's Range
120.54 - 122.69 - 52 Week Range
79.50 - 128.15 - Volume
575,671 - Avg. Volume
727,657 - Market Cap (intraday)
14.987B - Beta (5Y Monthly) 1.05
- PE Ratio (TTM)
75.94 - EPS (TTM)
1.60 - Earnings Date Nov 4, 2024
- Forward Dividend & Yield 0.28 (0.23%)
- Ex-Dividend Date Oct 18, 2024
- 1y Target Est
138.34
Revvity, Inc. provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, BACS-on-Beads, BIOCHIPs, Bioo Scientific,BoBs , chemagic, Chitas, DELFIA, DELFIA Xpress, DOPlify, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, explorer, Fontus, Genoglyphix, GSP, Haoyuan, IDS, IDS-i10 IDS-i10T, IDS-iSYS, iLab, iQ, JANUS, LabChip, LifeCycle, LimsLink, Migele, MultiPROBE, NEXTFLEX, NextPrep, Pannoramic, Panthera Puncher, PG-Seq, PGFind PKamp, PreNAT II, Prime, Protein Clear, ProteinEXact, QSigh, QuantiVac, RONIA, Sciclone, SimplicityChrom, Specimen Gate,Superflex, Symbio, T-SPOT, Touch, Twister, Vanadis, VariSpec, ViaCord VICTOR 2D, and Zephyr brand name. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
www.revvity.com11,000
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: RVTY
View MorePerformance Overview: RVTY
Trailing total returns as of 10/11/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: RVTY
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: RVTY
View MoreValuation Measures
Market Cap
14.99B
Enterprise Value
17.03B
Trailing P/E
75.94
Forward P/E
23.36
PEG Ratio (5yr expected)
3.07
Price/Sales (ttm)
5.55
Price/Book (mrq)
1.90
Enterprise Value/Revenue
6.29
Enterprise Value/EBITDA
23.29
Financial Highlights
Profitability and Income Statement
Profit Margin
6.26%
Return on Assets (ttm)
1.59%
Return on Equity (ttm)
2.51%
Revenue (ttm)
2.71B
Net Income Avi to Common (ttm)
197.34M
Diluted EPS (ttm)
1.60
Balance Sheet and Cash Flow
Total Cash (mrq)
1.95B
Total Debt/Equity (mrq)
50.79%
Levered Free Cash Flow (ttm)
585.85M
Research Analysis: RVTY
View MoreCompany Insights: RVTY
RVTY does not have Company Insights
Research Reports: RVTY
View MoreLowering target price to $128.00
REVVITY INC has an Investment Rating of HOLD; a target price of $128.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.
RatingPrice TargetWhat does Argus have to say about RVTY?
REVVITY INC has an Investment Rating of HOLD; a target price of $131.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.
RatingPrice TargetRaising target price to $131.00
REVVITY INC has an Investment Rating of HOLD; a target price of $131.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.
RatingPrice TargetRaising target price to $129.00
REVVITY INC has an Investment Rating of HOLD; a target price of $129.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.
RatingPrice Target